Favorable Response of 225Ac-PSMA in the Treatment of Castration-Resistant Prostate Cancer With High Bone Metastasis Burden

Clin Nucl Med. 2024 Apr 5. doi: 10.1097/RLU.0000000000005222. Online ahead of print.ABSTRACT225Ac-PSMA treatment demonstrated low hematologic toxicity for prostate cancer with diffuse red marrow infiltration. A 70-year-old man with diffuse bone metastases of castration-resistant prostate cancer received 225Ac-PSMA radiation therapy. After 1 treatment cycle, the patient's skeletal lesions demonstrated a significant response and a significant decrease in PSA. 225Ac-PSMA may be a promising therapeutic option for metastatic castration-resistant prostate cancer patients with high bone metastatic burden.PMID:38598741 | DOI:10.1097/RLU.0000000000005222
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research